Companies › Sutro Biopharma
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| STRO-004 Tissue Factor (TF) antagonist; antibody-drug conjugate targeting TF-expressing cancer cell | F3 | Phase 1 | Head and Neck Squamous Cell Carcinoma HNSCC | Dec 2027 |
| STRO-006 ITGB6-targeting antibody-drug conjugate | ITGB6 | Phase 1 | Head & Neck Squamous Cell Carcinoma | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07227168 | STRO-004 | Phase 1 | Head and Neck Squamous Cell Carcinoma HNSCC | Oncology | Dec 2027 |
| NCT07807345 | STRO-006 | Phase 1 | Head & Neck Squamous Cell Carcinoma | Oncology | Feb 2028 |
Cash and short-term investments of $164m on 2026-06-30; operating cash outflow about $163m a year; runway about 12 months at that burn, to Jul 2027
Press releases filed as 8-K in the last year:
Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.